ImYoo was selected as part of a global cohort as part 13th funding cycle of Illumina Accelerator in the San Francisco Bay Area. Read the official press release at Illumina.com:
We have released a technical note describing ImYoo's experimental platform for performing decentralized immune studies with small samples of capillary blood (0.1-0.5 mL) self collected by participant
ImYoo has partnered with Jumpcode Genomics to use Jumpcode’s RNA depletion technology to improve data quality and eliminate the uninformative sequences that were reduce the ability to gather valuable
ImYoo was selected as one of the award winners for QuickFire Immunology Challenge. As part of the award, ImYoo will receive lab space and access to the global Johnson & Johnson Innovation – JLABS (‘JL